YIXINTANG PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.74 CNY | +0.15% |
|
-3.80% | -14.77% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 13,206 | 19,830 | 22,959 | 18,782 | 13,803 | 11,765 | - | - |
| Enterprise Value (EV) 1 | 12,230 | 18,266 | 21,903 | 16,608 | 11,574 | 8,871 | 8,829 | 8,043 |
| P/E ratio | 21.9 x | 24.2 x | 24.7 x | 18.6 x | 25.2 x | 10.5 x | 8.69 x | 9.74 x |
| Yield | 1.29% | 0.9% | 0.78% | 1.27% | 1.73% | 1.87% | 2.26% | 2.21% |
| Capitalization / Revenue | 1.26 x | 1.57 x | 1.57 x | 1.08 x | 0.79 x | 0.58 x | 0.49 x | 0.5 x |
| EV / Revenue | 1.17 x | 1.44 x | 1.5 x | 0.95 x | 0.67 x | 0.44 x | 0.37 x | 0.34 x |
| EV / EBITDA | 12.4 x | 15.8 x | 16.9 x | 11 x | 10.6 x | 5.39 x | 4.08 x | 4.14 x |
| EV / FCF | 15.7 x | - | - | - | - | 4.61 x | 4.23 x | 3.79 x |
| FCF Yield | 6.36% | - | - | - | - | 21.7% | 23.6% | 26.4% |
| Price to Book | 2.95 x | 3.44 x | 3.49 x | 2.53 x | 1.78 x | 1.33 x | 1.15 x | 1.12 x |
| Nbr of stocks (in thousands) | 567,770 | 595,313 | 596,181 | 596,071 | 596,005 | 596,005 | - | - |
| Reference price 2 | 23.26 | 33.31 | 38.51 | 31.51 | 23.16 | 19.74 | 19.74 | 19.74 |
| Announcement Date | 2/27/20 | 2/7/21 | 3/14/22 | 3/17/23 | 3/19/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 10,479 | 12,656 | 14,587 | 17,432 | 17,380 | 20,161 | 24,085 | 23,658 |
| EBITDA 1 | 986.1 | 1,157 | 1,295 | 1,511 | 1,087 | 1,647 | 2,166 | 1,945 |
| EBIT 1 | 739.2 | 917.9 | 1,068 | 1,243 | 786.4 | 1,442 | 1,696 | 1,607 |
| Operating Margin | 7.05% | 7.25% | 7.32% | 7.13% | 4.52% | 7.15% | 7.04% | 6.79% |
| Earnings before Tax (EBT) 1 | 749.1 | 956.9 | 1,097 | 1,235 | 702.6 | 1,167 | 1,636 | 1,508 |
| Net income 1 | 603.9 | 790 | 921.6 | 1,010 | 549.4 | 943.9 | 1,339 | 1,217 |
| Net margin | 5.76% | 6.24% | 6.32% | 5.79% | 3.16% | 4.68% | 5.56% | 5.15% |
| EPS 2 | 1.063 | 1.378 | 1.556 | 1.697 | 0.9206 | 1.871 | 2.271 | 2.027 |
| Free Cash Flow 1 | 777.4 | - | - | - | - | 1,925 | 2,086 | 2,122 |
| FCF margin | 7.42% | - | - | - | - | 9.55% | 8.66% | 8.97% |
| FCF Conversion (EBITDA) | 78.84% | - | - | - | - | 116.85% | 96.29% | 109.12% |
| FCF Conversion (Net income) | 128.73% | - | - | - | - | 203.93% | 155.81% | 174.32% |
| Dividend per Share 2 | 0.3000 | 0.3000 | 0.3000 | 0.4000 | 0.4000 | 0.3686 | 0.4467 | 0.4367 |
| Announcement Date | 2/27/20 | 2/7/21 | 3/14/22 | 3/17/23 | 3/19/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4,089 | 3,995 | 3,970 | 4,060 | 5,406 | 4,436 | 4,240 | 4,137 | 4,567 | 5,100 | 4,782 | 4,882 | 5,945 | 5,709 | 5,957 |
| EBITDA 1 | 126.7 | 225.6 | 396.1 | 433.6 | - | - | - | - | - | - | 458.1 | 458.1 | 540.6 | 513.9 | 533.3 |
| EBIT 1 | 210.2 | 202.4 | 252.5 | 291.4 | 496.3 | 279.1 | 291.6 | 215.8 | - | 285.2 | 342.5 | 348.5 | 407.8 | 446.5 | 465.9 |
| Operating Margin | 5.14% | 5.07% | 6.36% | 7.18% | 9.18% | 6.29% | 6.88% | 5.22% | - | 5.59% | 7.16% | 7.14% | 6.86% | 7.82% | 7.82% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | 241.9 | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | 4.74% | - | - | - | - | - |
| EPS 2 | 0.2700 | 0.3035 | 0.4000 | 0.4400 | 0.5600 | 0.4017 | 0.4500 | 0.3000 | - | 0.4059 | 0.4276 | 0.4109 | 0.5025 | 0.4998 | 0.5322 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | 0.4142 | - | - | - | 0.4944 |
| Announcement Date | 3/14/22 | 4/29/22 | 8/18/22 | 10/27/22 | 3/17/23 | 4/20/23 | 8/19/23 | 10/30/23 | 3/19/24 | 4/26/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 977 | 1,564 | 1,056 | 2,174 | 2,229 | 2,894 | 2,936 | 3,722 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 777 | - | - | - | - | 1,925 | 2,086 | 2,122 |
| ROE (net income / shareholders' equity) | 14% | 15.8% | 15% | 14.5% | 6.97% | 12.9% | 13.7% | 12.7% |
| ROA (Net income/ Total Assets) | 7.89% | 9.14% | 7.79% | - | - | 5.95% | 6.25% | 6.8% |
| Assets 1 | 7,659 | 8,643 | 11,833 | - | - | 15,865 | 21,421 | 17,902 |
| Book Value Per Share 2 | 7.900 | 9.690 | 11.00 | 12.50 | 13.00 | 14.90 | 17.20 | 17.70 |
| Cash Flow per Share 2 | 1.730 | 1.740 | 3.030 | 4.190 | 3.550 | 3.260 | 3.430 | 4.900 |
| Capex 1 | 205 | 277 | 387 | 345 | 230 | 1,082 | 792 | 808 |
| Capex / Sales | 1.96% | 2.19% | 2.65% | 1.98% | 1.32% | 5.37% | 3.29% | 3.42% |
| Announcement Date | 2/27/20 | 2/7/21 | 3/14/22 | 3/17/23 | 3/19/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
19.74
CNY
Average target price
25.51
CNY
Spread / Average Target
+29.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.77% | 1.62B | |
| -32.21% | 15.27B | |
| -31.97% | 10.84B | |
| -30.42% | 6.06B | |
| +8.14% | 6.04B | |
| -11.41% | 5.86B | |
| -0.88% | 4.71B | |
| +52.19% | 4.29B | |
| -12.31% | 3.61B | |
| -14.86% | 3.33B |
- Stock Market
- Equities
- 002727 Stock
- Financials Yixintang Pharmaceutical Group Co., Ltd.
